Clinical Trial Update: A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

View source ↗

Summary

A completed Genentech trial evaluating psoriasis outcomes and safety events in patients with chronic moderate-to-severe plaque psoriasis (RESPONSE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Psoriasis | Status: COMPLETED